• Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues


Novo Nordisk Expands Clayton, North Carolina, Production Operations

Global pharmaceutical company Novo Nordisk plans to expand production operations in Clayton, North Carolina. The $.1 billion project is expected to create 1,000 new jobs in Johnston County.

The investment will include a new 1.4-million-square-foot fill and finishing manufacturing facility, adjacent to the company’s existing site, dedicated to producing current and future injectable treatments for people with obesity and other serious chronic diseases.

“It took us a century to reach 40 million patients, but through this expansion and continued investment in our global production, we’re building Novo Nordisk’s ability to serve millions more people living with serious chronic diseases in the future,” said Lars Fruergaard Jørgensen, president and CEO of Novo Nordisk. “This is yet another real signal of our efforts to scale up our production to meet the growing global need for our life-changing medicines and the patients of tomorrow.”

Partnering with the North Carolina Department of Commerce and the Economic Development Partnership of North Carolina (EDPNC) on this project were the North Carolina General Assembly, the North Carolina Department of Transportation, the North Carolina Community College System, Johnston Community College, the North Carolina Biotechnology Center, Duke Energy, Johnston County and Johnston County Economic Development.

“Novo Nordisk’s decision to expand its manufacturing capability with a multi-billion-dollar investment is testament to North Carolina’s top-notch workforce and long history of being a leader in the life sciences and biopharmaceutical industries,” noted Christopher Chung, CEO of the Economic Development Partnership of North Carolina. “This announcement is the largest life sciences investment in the state’s history, and we are proud that Novo Nordisk has confidence in the workforce, resources and partnerships North Carolina provides.”

Novo Nordisk A/S is a Danish multinational pharmaceutical company and currently operates production facilities in nine countries. The company manufactures and markets pharmaceutical products and services, specifically diabetes care medications and devices. Novo Nordisk's main product is the drug semaglutide, used to treat diabetes under the brand names Ozempic and Rybelsus and obesity under the brand name Wegovy.

“Because of the leadership of our county commissioners over the last 20 years, Johnston County will again be a part of the single largest life sciences manufacturing investment in the State of North Carolina, and quite possibly the largest in the U.S.,” added Chris Johnson, director of Economic Development for Johnston County.

Exclusive Research